Alkermes Overview
- Founded
- 1987

- Status
- Public
- Employees
- 2,211

- Stock Symbol
- ALKS

- Investments
- 13
- Share Price
- $29.30
- (As of Monday Closing)
Alkermes General Information
Description
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Contact Information
- Connaught House
- 1 Burlington Road
- Dublin D04 C5Y6
- Ireland
Alkermes Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$29.30 | $30.00 | $21.24 - $33.00 | $4.79B | 163M | 1.55M | -$0.38 |
Alkermes Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 4,141,306 | 3,620,812 | 2,991,254 | 2,919,237 |
Revenue | 1,200,866 | 1,173,751 | 1,038,756 | 1,170,947 |
EBITDA | 20,037 | 48,157 | (12,938) | (116,931) |
Net Income | (61,654) | (48,169) | (110,861) | (196,620) |
Total Assets | 1,977,845 | 2,024,484 | 1,949,730 | 1,805,403 |
Total Debt | 415,329 | 416,206 | 410,157 | 290,946 |
Alkermes Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.
Request a free trialAlkermes Comparisons
Industry
0000 000
000000 0
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAlkermes Competitors (26)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Tris Pharma | Private Debt Financed | Monmouth Junction, NJ | 000 | 000000000 - | ||
000000 00000000 | Corporation | Tokyo, Japan | 00000 | 00.000 | 00000000 | 00.000 |
000000000000 00000 | Corporate Backed or Acquired | Boca Raton, FL | 000000&0 | |||
00000 | Corporation | Mumbai, India | 00000 | 00000000 | ||
000000 00000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00.000 | 000000000 | 00.000 |
Alkermes Patents
Alkermes Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210371486-A1 | Il-2 fusion polypeptide compositions and methods of making and using the same | Pending | 11-May-2020 | 000000000 | |
US-20210347837-A1 | Immunostimulatory agents in combination with angiogenesis inhibitors | Pending | 15-Apr-2020 | 00000000000 | |
US-20210238177-A1 | Crystalline forms of 3-((1r,5s,9r)-9-ethoxy-3-azabicyclo[3.3.1]nonan-9-yl)-benzamide and salt forms thereof | Pending | 04-Feb-2020 | 0000000000 | |
US-20210253631-A1 | Methods of purification | Pending | 24-Jan-2020 | 000000000 | |
US-20210155636-A1 | Substituted macrocyclic compounds and related methods of treatment | Pending | 25-Nov-2019 | C07D498/08 |
Alkermes Executive Team (35)
Alkermes Board Members (16)
Name | Representing | Role | Since |
---|---|---|---|
Brian Mckeon | Self | Board Member | 000 0000 |
Cato Laurencin Ph.D | Alkermes | Board Member | 000 0000 |
David Anstice | Self | Board Member | 000 0000 |
David Daglio | Alkermes | Board Member | 000 0000 |
Emily Alva | Self | Board Member | 000 0000 |
Alkermes Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAlkermes Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.
Request a free trialAlkermes Investments & Acquisitions (13)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000 0000000 | 25-Nov-2019 | 0000000000 | 00000 | Drug Discovery | 00000 000 |
0000000 00000 | 25-Aug-2014 | 00000 0000 | 0000 | Drug Delivery | 000000 00 |
0000000000000 | 26-Nov-2013 | 00000 0000 | 000.00 | Drug Discovery | 00000 000 |
0000000 00000 | 11-Sep-2013 | 00000 0000 | 0000 | Drug Delivery | 000000 00 |
Acceleron Pharma | 23-Dec-2011 | Later Stage VC | 000.00 | Drug Discovery | 0000000 0 |
Alkermes Exits (8)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
0000000 0000000000 | 25-Aug-2014 | 00000 00000 00 | 0000 | Completed |
|
0000000 0000000000 | 11-Sep-2013 | 00000 00000 00 | 0000 | Completed |
|
000000000 000000 | 23-Dec-2011 | 00000 00000 00 | 000.00 | Completed |
|
0000000 0000000000 | 12-Jul-2011 | 00000 00000 00 | 0000 | Completed |
|
Acceleron Pharma | 15-Dec-2009 | Later Stage VC | 0000 | Completed |